



CIN NO.: L24230WB1982PLC034492

Date: 13th August, 2020

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,


Sub: Outcome of Board Meeting held on 13th August, 2020

This is to inform you that, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held at its Registered Office on Thursday, 13th August, 2020 (**commenced at 12:00 Noon and concluded at 12:50 P.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Unaudited Financial Results of the Company for the 01st quarter ended 30th June, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Limited Review Report by the Statutory Auditors on Standalone Unaudited Financial Results for 1st quarter ended 30th June, 2020.
3. 39th Annual General Meeting (AGM) will be held on Monday, 21st September, 2020, at 01:30 P.M. IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM").
4. The Notice of 39th Annual General Meeting (AGM) of the Company along with Directors Report, Corporate Governance Report and Management Discussion and Analysis Report of the Company for the financial year ended 31/03/2020. The Notice convening the 39th AGM will be sent to the Stock Exchange in due course.
5. The Register of Members & Share Transfer Books of the Company Pursuant to Regulation 42 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, will remain closed from Tuesday, September 15, 2020 to Monday, September 21, 2020 (both days inclusive) for the purpose of Annual General Meeting (AGM) schedule to be held on 21st September, 2020.
6. In compliance with provision of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, the cut-off date to record the entitlement of Members to cast their votes for the businesses to be transacted at the ensuing 39th AGM of the Company is fixed as on 14th September, 2020. The e-Voting period will begin on September 17, 2020 (9:00 A.M.) and end on September 20, 2020 (5:00 P.M.).
7. Mr. Rahul Bhutoria, Prop: M/s. Bhutoria & Associates (F.R. No. 329621E), Practicing Chartered Accountant (Membership No. 304193) has been appointed as the scrutinizer for

Email: investors@adinathbio.com
<http://www.adinathbio.com>

4, N. S. Road, 1st Floor, Kolkata – 700 001
Telephone: +91-33-22315718





CIN NO.: L24230WB1982PLC034492

the remote E-voting process as well as Ballot papers/Poll process at the forthcoming 39th Annual General Meeting.

8. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith.


This information is also available on Company's website: www.adinathbio.com and on the stock exchange website: www.cse-india.com.

The Company would be publishing Extract of Unaudited Financial Result for the 01st Quarter ended 30-06-2020, in accordance with Regulation 47(1) (b) of the Listing Regulation.

Request you to kindly take the above on record.

Thanking you,
Yours faithfully,
For Adinath Bio-Labs Limited

Kishan Singh
(Whole-Time Director)
(DIN: 07526266)
Encl.: As above.




CC:

To,
National Securities Depository Limited
4th Floor, 'A' Wing, Trade World,
Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel
MUMBAI - 400 013

To,
Central Depository Services (India) Limited
Marathon Futurex, A-Wing,
25th Floor, Mafatlal Mills Compound,
N M Joshi Marg, Lower Parel (East)
MUMBAI - 400 013

To,
Adroit Corporate Services Pvt. Ltd
19/20, Jaferbhoy Indl. Estate,
Makwana Road, Marol Naka,
Andheri (E),
Mumbai – 400059

Statement of Standalone Unaudited Financial Results for the 1st Quarter ended 30th June, 2020					
(Amount in Rs.)					
Sl. No.	Particulars	Quarter Ended			Year ended
		Unaudited	Audited	Unaudited	Audited
		30/06/2020	31-03-2020 (Refer note no.5)	30/06/2019	31/03/2020
1	Income from operations				
	(a) Net Sales / income from operations	-	-	-	-
	(b) Other Income	63,077	62,904	62,904	253,000
	Total income from operations (net)	63,077	62,904	62,904	253,000
2	Expenses				
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-
	(b) Employee benefits expense	136,054	136,081	142,233	529,506
	(c) Finance Cost	-	-	-	-
	(d) Depreciation and amortisation expense	6,161	13,394	13,394	53,576
	(e) Other expenses	258,479	4,314,670	261,068	4,772,554
	Total expenses	400,694	4,464,145	416,695	5,355,636
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(337,617)	(4,401,241)	(353,791)	(5,102,636)
4	Exceptional & Extraordinary Items	6,000,000	-	6,025,000	29,107,012
5	Profit / (Loss) before Tax (3 ± 4)	(6,337,617)	(4,401,241)	(6,378,791)	(34,209,648)
6	Tax expense				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
	Earlier Years	-	-	-	-
	Total Tax Expenses	-	-	-	-
7	Net Profit/(Loss) after tax(5 ± 6)	(6,337,617)	(4,401,241)	(6,378,791)	(34,209,648)
8	Other Comprehensive Income / (Loss)	-	-	-	-
9	Total Comprehensive Income / (Loss) (7 ± 8)	(6,337,617)	(4,401,241)	(6,378,791)	(34,209,648)
10	Paid-up equity share capital	220,742,560	220,742,560	220,742,560	220,742,560
	(Face Value of the Share shall be indicated in Re.)	1	1	1	1
11	Earnings Per Share (not annualised except for year ended):				
	Basic & Diluted	(0.03)	(0.02)	(0.03)	(0.15)



Notes:

- 1 The above Unaudited Financial results have been reviewed by the Audit committee at their meeting and adopted by the Board of Directors at their meeting held on 13th August, 2020.
- 2 The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The company is engaged in the business of Trading in Commodities and it's allied products and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The Statutory Auditors of the Company have conducted a limited review of the above standalone unaudited financial results of the Company for the quarter ended June 30, 20120 and issued an unqualified report in this behalf.
- 5 The figures for the quarter ended 31st March, 2020, are the balancing figures between audited figures in respect of the full financial year ended 31st March, 2020 and the year to date figures upto the third quarter of financial year 2019-20.
- 6 An amount of Rs.60.00 lacs have been provided and charged to profit and loss account under exceptional items on account of provision for doubtful receivables for the quarter ended 30th June, 2020.
- 7 The Company has internally perfomed sensitivity analysis on the assumptions used and based on current estimates, the Company expects that the carrying amount of these assets, as reflected in the balance sheet as at 30th June 2020, are fully recoverable as on reporting date. The management has also estimated the future cash flows for the Company with the possible effect that may result from the Covid-19 pandemic and does not foresee any adverse impact on its ability to continue as going concern and in meeting its liabilities as and when they fall due. The actual impact of Covid-19 pandemic may be differed from the estimated as at the date of approval of these financial results.
- 8 Provisions for taxations will be made at the end of the year.
- 9 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

By order of the Board
For Adinath Bio-Labs Limited



Kishan Singh
Whole Time Director

DIN :07526266

Date: 13th August, 2020

Place: Kolkata

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Adinath Bio-Labs Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the 01st quarter ended on 30th June, 2020 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.
Chartered Accountants
FRN: 003822C


Kamal Piyush
Partner

Membership No.: 083399
Place: Kolkata
Date: 13/08/2020
UDIN: 20083399AAAAAZ1019



CIN NO.: L24230WB1982PLC034492

Date: 13th August, 2020

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-


- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Kishan Singh, Whole Time Director of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the quarter ended on 30th June, 2020.

You are requested to take the above information in your records.

Thanking you,
Yours faithfully,

For Adinath Bio-Labs Limited



Kishan Singh
(Whole-Time Director)
DIN: 007526266